Techniques for preparing and handling the Thorium targets and extraction of the Ac225 have been worked out. LANL has been producing 1.3-2 mCi10-hour hour exposure. They have already distributed 250 mCi to researchers. Stage 2 plans to increase this to 50-100 mCi. Looking forward to the day when clinical quantities of Ac225 may be required, they are working with companies and hospitals and are developing an FDA Drug Master File (DMF) for support in Phase I trials.
Presented by: Kevin John, PhD, Science Program Officer, Los Alamos National Laboratory, Los Alamos, New Mexico, United States